30-Second Takeaway
- Updated inpatient cirrhosis guidance emphasizes complication-specific, transplant-focused care pathways for hospitalized patients.
- Primary palliative care delivered by trained hepatologists is noninferior to specialist palliative care in end-stage liver disease.
- Elraglusib plus gemcitabine/nab-paclitaxel improves survival in first-line metastatic pancreatic cancer with acceptable toxicity.
- Early thiopurine or methotrexate use in Crohn’s disease significantly lowers long-term intestinal resection risk.
- Mid-range intestinal ultrasound systems perform comparably to high-end units for objective IBD activity assessment.
Week ending April 18, 2026
New data reshaping inpatient cirrhosis care, IBD monitoring and treatment strategy, and GI oncology therapeutics
Practical inpatient roadmap for managing cirrhosis complications
This narrative review synthesizes updated guidelines for inpatient management of cirrhosis and its major complications. It emphasizes structured approaches to acute variceal bleeding, infections, ascites, hepatic encephalopathy, and renal injury in hospitalized patients. The article highlights the importance of early recognition of decompensation and timely evaluation for liver transplantation. It provides explicit, evidence-based practice recommendations intended for real-time use on the hospital wards.
Hepatologist-led primary palliative care is noninferior to specialist care in ESLD
This multicenter cluster randomized trial compared palliative care delivered by trained hepatologists versus palliative care specialists in 935 US patients with end-stage liver disease. Both groups received four structured palliative visits over three months using a standardized checklist. Quality of life improved similarly in both arms, and hepatologist-delivered palliative care met prespecified noninferiority criteria versus specialist care. Symptom burden, distress, depression, satisfaction, and mortality did not differ meaningfully, supporting integration of primary palliative care into hepatology services.
Elraglusib plus GnP improves survival in first-line metastatic pancreatic cancer
This open-label phase 2 trial randomized untreated metastatic pancreatic ductal adenocarcinoma patients 2:1 to elraglusib plus gemcitabine/nab-paclitaxel or chemotherapy alone. Elraglusib added to gemcitabine/nab-paclitaxel improved median overall survival from 7.2 to 10.1 months, reducing death risk by 38%. One-year survival increased from 22.3% with chemotherapy alone to 44.1% with the elraglusib combination. Toxicity was manageable but included higher grade ≥3 neutropenia and fatigue in the combination arm. Correlative work suggested baseline immune-related circulating factors and increased intratumoral cytotoxic cells were associated with benefit. These data justify a planned phase 3 trial and suggest a potentially practice-changing first-line regimen if confirmed.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.